33 63 50 48 0 20 40 60 80 100 2.5 mg (n=9) 5 mg (n=8) 10 mg (n=10) All patients (n=27) PEAK and PINNACLE – Key question: Why are the APEX top two dose levels selected? 0 5 10 15 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg ETDRS Letters Weeks APEX Mean Change in BCVA in patients completing Week 12 The KSI-101 5 mg and 10 gm dose levels were selected to advance into PEAK and PINNACLE, based on: • Greater visual acuity gains achieved, particularly 15-letter gainers • Similar safety profile across all dose levels 2.5 mg 9 9 9 9 9 5 mg 8 8 8 8 8 10 mg 10 10 10 10 10 N values Patients, % APEX ≥15 letter gainers in patients completing Week 12 94 Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that completed the Week 12 visit by the cutoff date of 14-Jul-25 and meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion)